List view / Grid view
7 June 2016 | By Victoria White, Digital Content Producer
The primary endpoint primary endpoint was a multicomponent measure evaluating improvement of physical function, cognitive function, and disability...
7 June 2016 | By Victoria White, Digital Content Producer
Epigallocatechin gallate, together with a cognitive stimulation protocol, might improve some cognitive domains in individuals with Down’s syndrome...
7 June 2016 | By Victoria White, Digital Content Producer
Myovant Sciences is a biopharmaceutical company focused on delivering innovative women’s health and prostate cancer therapeutics...
7 June 2016 | By Victoria White, Digital Content Producer
Aprea presented clinical data from the Phase Ib part of the ongoing PiSARRO Phase Ib/II trial of APR-246 at the ASCO annual meeting...
7 June 2016 | By Victoria White, Digital Content Producer
Byvalson is the first and only fixed-dose combination (FDC) of a beta blocker (BB) and angiotensin II receptor blocker (ARB) available in the US...
7 June 2016 | By Victoria White, Digital Content Producer
Novartis has announced new data for the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) in non-small cell lung cancer (NSCLC) and melanoma...
6 June 2016 | By Victoria White, Digital Content Producer
Coagadex is indicated for the treatment and prophylaxis of bleeding episodes and for perioperative management in patients with hereditary factor X deficiency...
6 June 2016 | By Victoria White, Digital Content Producer
Immunocore has announced positive data from the first in human, Phase I clinical trial of its lead ImmTAC, IMCgp100...
6 June 2016 | By Victoria White, Digital Content Producer
POL6014 is a highly selective, potent and reversible inhibitor of hNE. Increased levels of hNE is associated with cystic fibrosis...
6 June 2016 | By Victoria White, Digital Content Producer
Keytruda is a humanised monoclonal antibody that works by increasing the ability of the body’s immune system to help detect and fight tumour cells...
6 June 2016 | By CPhI
The new Finished Dosage Formulation (FDF) event will be the first global pharma platform dedicated to the manufacture, development and supply of finished dosage forms...
6 June 2016 | By Victoria White, Digital Content Producer
Sanofi and Regeneron have announced that a one-year Phase III study evaluating investigational dupilumab met its primary and key secondary endpoints.
6 June 2016 | By Victoria White, Digital Content Producer
Ganymed announced data from its randomised Phase II clinical study of IMAB362 in first-line treatment of gastric cancer at the ASCO 2016 Annual Meeting...
6 June 2016 | By Victoria White, Digital Content Producer
Data were presented from two early-phase trials evaluating Lilly's Alimta and Cyramza in combination with Merck's Keytruda in patients with NSCLC...
6 June 2016 | By Victoria White, Digital Content Producer
New data for Bristol-Myers Squibb’s Opdivo has been presented at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO)...
